We are in this together. From oxygen hoods to ventilators, our scientists and engineers across the agency are uniting to join the fight against coronavirus. Tune in to #NASAScience Live on June 25 at 3 p.m. EDT to watch this nationwide effort.
Category: biotech/medical – Page 1,938
Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient on Private Insurance
🤔
Gilead’s Covid-19 drug remdesivir will be priced at $3,120 for a typical U.S. patient with commercial insurance.
Gilead Sciences Inc. detailed its pricing plans for Covid-19 drug remdesivir, saying it will charge U.S. hospitals $3,120 for a typical patient with commercial insurance.
The drugmaker on Monday disclosed its pricing plans as it prepares to begin charging for the drug in July. The U.S. has been distributing remdesivir donated by Gilead since the drug was authorized for emergency use in May.
How Chinese tech giants are disrupting insurance industry with pooled funds
However, the situation has been improving as Chinese tech giants including e-commerce company Alibaba, search engine Baidu, on-demand delivery company Meituan Dianping, ride-hailing operator Didi Chuxing and smartphone maker Xiaomi now offer more affordable health care plans via mutual aid platforms, which operate as a collective claim-sharing mechanism.
China’s online mutual aid platforms are disrupting old school insurance companies by leveraging big data and internet finance technologies to offer low cost medical coverage.
Human Trials of Plasma Exchange
Animal experiments demonstrating the anti-aging effects of exchanging young blood plasma for old have been prominent in the last two months. Several groups are saying it’s time to translate their findings into human trials. But I’ve recently learned that others have been doing this for several years. What can we learn from their results to guide the next steps in experimentation?
I had never heard of Grifols, the Spanish pharmaceutical company that is the world’s largest supplier of albumin. Since 2005, Grifols has been quietly funding world leaders in plasma exchange research in humans. Albutein ® is their brand-name solution of human albumin.
Last month, the first results of the Grifol’s AMBAR trial were released. (AMBAR stands for A lzheimer’s M odulation B y A lbumin R eplacement). It was a much larger-scale phase 2.5 trial, with 496 subjects recruited from sites in Spain and USA, and treated for 14 months. A single treatment consisted of removing 2.5 to 3 litres of blood (more than half the body’s inventory) and replacing it with Albutein. Patients began with 6 weekly treatments, and thereafter there were 12 monthly smaller plasma replacements (0.7 litres), again with Albutein.
Coronavirus death toll surpasses 500,000 worldwide
More than 500,000 people throughout the world have died of the new coronavirus, according to data from Johns Hopkins University. The staggering milestone comes as virus cases have surged in the U.S. in recent weeks, and as South America has emerged as a virus hotspot.
More than a quarter of the world’s reported coronavirus deaths have occurred in the U.S., where 31 states have seen a jump in cases compared to two weeks ago. The number of new confirmed coronavirus cases nationwide hit a record high of 45,300 on Friday — a more than 5,000-case spike from the day before.
In Texas and Florida, governors are now rolling back reopening measures in an effort to stem the virus’ spread. The intensive care units in some Texas hospitals are now 100% full, after the state broke hospitalization records for 15 days in a row.
Ohio Supercomputer Center Researchers Analyse Twitter Posts Revealing Polarization in Congress on COVID-19
June 25, 2020 — The rapid politicization of the COVID-19 pandemic can be seen in messages members of the U.S. Congress sent about the issue on the social media site Twitter, a new analysis found.
Using artificial intelligence and resources from the Ohio Supercomputer Center, researchers conducted an analysis that covered all 30,887 tweets that members sent about COVID-19 from the first one on Jan. 17 through March 31.
Lockheed Martin’s New F-21 Fighter on offer to India has F-22 and F-35 ‘DNA’
New Delhi could select its new fighter in 2019. If it picks the F-21 and opts to keep Lockheed’s designation for the type, it rightfully could claim to be the first operator of a brand-new fighter.
Lockheed Martin in mid-February 2019 offered to sell India a new fighter the company calls the “F-21.”
Only it doesn’t look like a new fighter at all. The F-21 looks like an F-16.
Could Doomsday Bunkers Become the New Normal?
He stresses that these are not “luxury bunkers” for the top 1 percent, and only a small part of the calls are coming from Doomsday preppers or Cold War-era holdovers. Rather, about two-thirds of his business comes from consumers who pay approximately $25,000 for an underground livable dwelling. Since the outbreak of the coronavirus pandemic, Mr. Woodworth said he has been unable to keep up with the demand.
When we were told to stay inside our homes, a portion of the population quietly went below ground.